Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ocugen Inc.

http://ocugen.com

Latest From Ocugen Inc.

Deal Watch: Gilead To Use Insitro’s AI/Functional Genomics Tech For NASH Targets

Start-up Insitro will attempt to optimize up to five NASH targets for Gilead under three-year alliance. Catalent buys gene therapy CDMO Paragon for $1.2bn, Boehringer partners with PureTech in GI cancer, while Fibrocell inks gene therapy pact with Castle Creek.

Deals Business Strategies

Pipeline Watch: Phase III Progress With Tecentriq, Rolontis And ADV7103

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals

Pipeline Watch: Phase III Progress With Eylea, Tecentriq And HTX-011

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals

Ocugen Heads Toward Phase III In Dry Eye With Potential Benefits Over Older Drugs

Biotech hopes to counter established Restasis and Xiidra in dry eye with a combination of two approved ophthalmology eye drops, offering quicker onset of action, tolerability and strong efficacy.
Clinical Trials Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ocugen Inc.
  • Senior Management
  • Shankar Musunuri, PhD, Chmn. & CEO
    Sanjay S Subramanian, CFO
    Daniel Jorgensen, MD, CMO
    Rasappa Arumugham, PhD, CSO
  • Contact Info
  • Ocugen Inc.
    Phone: (484) 328-4701
    5 Great Valley Pkwy., Ste. 160
    Malvern, PA 19355
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register